Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization

FEBS Journal

Volumn 275, Issue 9, 2008, Pages 2296-2304

  Müller, Nicole ^a   Wyzgol, Agnes ^a   Münkel, Sabine ^b   Pfizenmaier, Klaus ^b   Wajant, Harald ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF STUTTGART   (Germany)

Author keywords

FAP; NF B; Oligomerization, OX40L; Single chain

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 8; MEMBRANE ANTIGEN; OX40 LIGAND; SEPRASE;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CROSS LINKING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMOBILIZED CELL; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN SYNTHESIS; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CROSS-LINKING REAGENTS; DIMERIZATION; HUMANS; KIDNEY; OX40 LIGAND; RECOMBINANT FUSION PROTEINS; SOLUBILITY; SURFACE PROPERTIES;

EID: 42449106534     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06382.x     Document Type: Article

References (32)

1. Locksley RM, Killeen N Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487 501.
2. Barr TA, Carlring J Heath AW (2006) Co-stimulatory agonists as immunological adjuvants. Vaccine 24, 3399 3407.
3. Croft M (2003) Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 14, 265 273.
4. Sugamura K, Ishii N Weinberg AD (2004) Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4, 420 431.
5. Fesik SW (2000) Insights into programmed cell death through structural biology. Cell 103, 273 282.
6. Bodmer JL, Schneider P Tschopp J (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27, 19 26.
7. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K et al. (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793 802.
8. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W, Pfizenmaier K Wajant H (2007) Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 14, 2021 2034.
9. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A Tschopp J (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187, 1205 1213.
10. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, Tinel A, Deperthes D, Calderara S, Schulthess T et al. (2003) Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 23, 1428 1440.
11. Greaney P, Nahimana A, Lagopoulos L, Etter AL, Aubry D, Attinger A, Beltraminelli N, Huni B, Bassi I, Sordat B et al. (2006) A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk Res 30, 415 426.
12. Aoki K, Kurooka M, Chen JJ, Petryniak J, Nabel EG Nabel GJ (2001) Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat Immunol 2, 333 337.
13. Samel D, Muller D, Gerspach J, Assohou-Luty C, Sass G, Tiegs G, Pfizenmaier K Wajant H (2003) Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J Biol Chem 278, 32077 32082.
14. Bremer E, Ten Cate B, Samplonius DF, de Leij LF Helfrich W (2006) CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukaemia. Blood 107, 2863 2870.
15. Haswell LE, Glennie MJ Al-Shamkhani A (2001) Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 31, 3094 3100.
16. Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF Kornbluth RS (2006) Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 80, 1762 1772.
17. Muhlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G, Scheurich P, Moosmayer D, Tschopp J Wajant H (2000) The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 275, 32208 32213.
18. Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, Peters N, Scheurich P Pfizenmaier K (2001) Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20, 4101 4106.
19. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG Ashkenazi A (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signalling. J Biol Chem 280, 2205 2212.
20. Rabu C, Quemener A, Jacques Y, Echasserieau K, Vusio P Lang F (2005) Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem 280, 41472 41481.
21. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L Helfrich W (2004) Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 109, 281 290.
22. Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF Helfrich W (2005) Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 280, 10025 10033.
23. Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, Khawli LA, Hu P Epstein AL (2007) Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res 13, 2758 2767.
24. Stieglmaier J, Bremer E, Kellner C, Liebig TM, Ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Buhring HJ, Greil J et al. (2008) Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother 57, 233 246.
25. Morris NP, Peters C, Montler R, Hu HM, Curti BD, Urba WJ Weinberg AD (2007) Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol 44, 3112 3121.
26. Zubairi S, Sanos SL, Hill S Kaye PM (2004) Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur J Immunol 34, 1433 1440.
27. Humphreys IR, Edwards L, Walzl G, Rae AJ, Dougan G, Hill S Hussell T (2003) OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J Immunol 170, 6125 6132.
28. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, Urba WJ, Alvord G, Bunce C Shields J (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 15, 2160 2169.
29. Pan PY, Zang Y, Weber K, Meseck ML Chen SH (2002) OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther 6, 528 536.
30. Morris A, Vetto JT, Ramstad T, Funatake CJ, Choolun E, Entwisle C Weinberg AD (2001) Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res Treat 67, 71 80.
31. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A Shu S (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60, 5514 5521.
32. Gri G, Gallo E, Di Carlo E, Musiani P Colombo MP (2003) OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J Immunol 170, 99 106.